Method of treating amyotrophic lateral sclerosis

The compound (5R,6S)-10,11-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH-spiro[benzo[b][1,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide addresses ALS treatment inadequacies by targeting TDP-43 aggregation and inflammation, enhancing motor function and reducing tumor growth with minimal side effects.

WO2026240831A1PCT designated stage Publication Date: 2026-11-19PASITHEA THERAPEUTICS CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/016808
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-08-18
Filing Date
2026-02-26
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current treatments for amyotrophic lateral sclerosis (ALS) are inadequate due to their toxicity and inability to effectively target both TDP-43 aggregation and inflammation, which are central to the disease's pathophysiology.

Method used

Administration of (5R,6S)-10,11-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH-spiro[benzo[b][1,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide or its pharmaceutically acceptable salts, which act as MEK inhibitors to modulate TDP-43 aggregation and inflammation.

Benefits of technology

The compound shows therapeutic benefits in ALS by improving motor function and reducing tumor growth without significant weight loss, indicating potential as a safer and more effective treatment option.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026016808_19112026_PF_FP_ABST
    Figure US2026016808_19112026_PF_FP_ABST
Patent Text Reader

Abstract

Provided herein are methods of treating amyotrophic lateral sclerosis, comprising administering a therapeutically effective amount of (5R,6S)-10,11-difluoro-12-((2-fluoro-4- iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-1H-spiro[benzo[b][1,5,4]oxathiazecine- 3,1'-cyclopropane] 2,2-dioxide or a pharmaceutically acceptable salt or solid form thereof (Compound 1), or a tablet formulation of Compound 1.
Need to check novelty before this filing date? Find Prior Art

Description

Attorney Docket No. 14763-027-228METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSISCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 805,237, filed May 13, 2025, and U.S. Provisional Patent Application No. 63 / 866,072, filed August 18, 2025, the disclosure of each of which is incorporated by reference herein in its entirety.FIELD

[0002] Provided herein are methods of treating amyotrophic lateral sclerosis, comprising administering a therapeutically effective amount of (5R,6S)-10,ll:-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide or a pharmaceutically acceptable salt or solid form thereof (Compound 1), or a tablet formulation of Compound 1.

[0003] In certain embodiments, provided herein is (5R,6S)-10,ll-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide or a pharmaceutically acceptable salt or solid form thereof (Compound 1), for use in methods of treating amyotrophic lateral sclerosis.BACKGROUND

[0004] Amyotrophic lateral sclerosis (ALS) remains a fatal disease despite a deepening understanding of its pathophysiology. Hallmark features of ALS pathology are immune-mediated neuronal damage (i.e., inflammation) and, in most forms, mis-localization of intracellular TDP-43. Mitogen-activated protein kinases (MAPK) extracellular signal-regulated kinase 1 / 2 (MEK) have been shown to be involved with both TDP-43 mediated neurodegeneration and inflammation. TDP-43 is a substrate of MEK, a central kinase in the MAPK / extracellular signal-regulated kinases (ERK) signaling pathway. MEK has been shown to contribute to novel phosphorylation of TDP-43 in human cells. The multifaceted complexity of ALS may require a treatment targeting intersecting pathways including modulation of TDP-43 aggregation and inflammation. There is a significant need for compounds, such as novel MEK inhibitors, that show benefit in ALS but less toxicity than current medications.SUMMARY

[0005] Provided herein are methods of treating amyotrophic lateral sclerosis, comprising administering a therapeutically effective amount of (5R, 6 S)-l 0,11 -difluoro- 12-((2-fluoro-4-1NAI-5002374383vliodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide or a pharmaceutically acceptable salt or solid form thereof (Compound 1), to a patient having amyotrophic lateral sclerosis.

[0006] Provided herein are also methods of treating amyotrophic lateral sclerosis, comprising administering to a patient having amyotrophic lateral sclerosis a tablet formulation comprising about 1% to about 10% of (5R,6S)-10,ll-difhioro-12-((2-fhioro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide or a pharmaceutically acceptable salt or solid form thereof (Compound 1), about 42% to about 46% microcrystalline cellulose, about 22% to about 26% lactose monohydrate, about 13% to about 17% pregelatinized starch, about 8% to about 12% crospovidone, about 0.3% to about 0.7% colloidal silicon dioxide, and about 0.05% to about 0.7% magnesium stearate, where the percentages are by weight based on total weight of the tablet.BRIEF DESCRIPTION OF DRAWINGS

[0007] FIG. 1 and FIG. 2 provide data of Compound 1 efficacy in a preclinical SOD1 mouse study.

[0008] FIGS. 3A and 3B. Compound 1 treated mice showed non-significant trends towards improved performance in the beam walk and rotarod motor function assays. The beam walk assay (FIG. 3A) was performed at 19 weeks of age with mice videotaped and scored for time to traverse the beam and the number of slips. Lower slips / speed scores indicate improved performance as seen for the Compound 1 treated mice. The rotarod test (FIG. 3B) was also done at week 19. The time it took for mice to fall is plotted. Compound 1 treated mice remained on the rotarod for a longer time than control mice.

[0009] FIGS. 4A and 4B. Both Compound 1 and trametinib treated mice completely suppressed the growth of hepatocellular tumors (FIG. 4A). Compound 1 did not cause any weight loss in these mice while a dose of trametinib with equal anti-tumor activity caused greater weight loss with a significant decline seen at Day 9 (FIG. 4B).

[0010] FIGS. 5A and 5B. In a lung cancer xenograft model Compound 1 showed increasing reduction of tumor volume as dose increased from 2.5-10 mg / kg (FIG. 5A). Western blot analysis of tumor lysates showed the pERK / total ERK levels decreased from 21% at the lowest dose to 75% at the highest dose consistent with the changes in tumor volume reduction (FIG.5B)2NAI-5002374383vlDETAILED DESCRIPTION[Oil] The details of construction and the arrangement of components set forth in the following description or illustrated in the drawings are intended to describe non-limiting embodiments. Other embodiments and different ways to practice the invention are expressly included. Also, the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of “including,” “comprising,” or “having,” “containing”, “involving”, and variations thereof herein, is meant to encompass the items listed thereafter and equivalents thereof as well as additional items.

[0012] As used herein, the terms “comprising” and “including” can be used interchangeably. The terms “comprising” and “including” are to be interpreted as specifying the presence of the stated features or components as referred to, but does not preclude the presence or addition of one or more features, or components, or groups thereof. Additionally, the terms “comprising” and “including” are intended to include examples encompassed by the term “consisting of’. Consequently, the term “consisting of’ can be used in place of the terms “comprising” and “including” to provide for more specific embodiments of the invention.

[0013] The term “consisting of’ means that a subject-matter has at least 90%, 95%, 97%, 98% or 99% of the stated features or components of which it consists. In another embodiment the term "consisting of’ excludes from the scope of any succeeding recitation any other features or components, excepting those that are not essential to the technical effect to be achieved.

[0014] As used herein, the term “or” is to be interpreted as an inclusive “or” meaning any one or any combination. Therefore, “A, B or C” means any of the following: “A; B; C; A and B; A and C; B and C; A, B and C”. An exception to this definition will occur only when a combination of elements, functions, steps, or acts are in some way inherently mutually exclusive.1. Definitions

[0015] As used above, and throughout the description of the invention, the following terms, unless otherwise indicated, shall be understood to have the following meanings.

[0016] As used in this application, the singular form “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise.

[0017] “Compound 1” is meant to refer to (5R,6S)-10,ll-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide or a pharmaceutically acceptable salt thereof, including solid forms of the free base and salts thereof. The compound chemically named 10,11 -difluoro- 12-3NAI-5002374383vl((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide belongs to a novel class of MEK1 / 2 inhibitors having a macrocyclic scaffold, which has been disclosed in US 9,034,861, which is herein incorporated by reference in its entirety. Solid forms of (5R,6S)-10,ll-difluoro-12-((2 -fluoro-4-iodophenyl)amino)-5,6-dihydroxy -4,5,6, 7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide have been described in International Application No. PCT / US2025 / 010064 (filed January 2, 2025), Chinese priority application No. PCT / CN2024 / 070736 (filed January 5, 2024) and US provisional application No. 63 / 722,522 (filed November 19, 2024). (5R,6S)-10,ll-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide, its corresponding diastereoisomers, and its solid forms have also been disclosed in International Application No. PCT / US2025 / 010070 (filed January 2, 2025) and US provisional application Nos. 63 / 618,167 and 63 / 722,523 (filed January 5, 2024 and November 19, 2024 respectively). All of the abovementioned applications are herein incorporated by reference in their entirety.

[0018] The term “solid form” refers to a crystal form or an amorphous form or a mixture thereof of (5R,6S)-10,l 1 -difluoro- 12-((2-fluoro-4-iodophenyl)amino)-5, 6-dihydroxy-4, 5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide or a pharmaceutically acceptable salt thereof.

[0019] As used herein, and unless otherwise indicated, a chemical compound or composition that is “substantially free” of another chemical compound or composition means that the compound or composition contains, in certain embodiments, less than about 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.05%, or 0.01% by weight of the other compound or composition.

[0020] As used herein, and unless otherwise specified, a compound that is “substantially chemically pure” is substantially free from other chemical compounds ( / .<?., chemical impurities). In certain embodiments, a compound that is substantially chemically pure contains less than about 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.05%, or 0.01% of one or more other chemical compounds on a weight basis. The detection of other chemical compounds can be accomplished by any method apparent to a person of ordinary skill in the art, including, but not limited to, methods of chemical analysis, such as, e.g., mass spectrometry analysis, spectroscopic analysis, thermal analysis, elemental combustion analysis, and / or chromatographic analysis.4NAI-5002374383vl

[0021] As used herein and unless otherwise indicated, the terms “pure” when applied to a chiral compound or “stereoisomer” or “stereomerically pure” means one stereoisomer of a compound disclosed herein that is substantially free of other stereoisomers of that compound. For example, a stereomerically pure compound having one chiral center will be substantially free of the opposite enantiomer of the compound. A stereomerically pure compound having two chiral centers will be substantially free of other diastereomers of the compound. A typical stereomerically pure compound comprises greater than about 80% by weight of one stereoisomer of the compound and less than about 20% by weight of other stereoisomers of the compound, greater than about 90% by weight of one stereoisomer of the compound and less than about 10% by weight of the other stereoisomers of the compound, greater than about 95% by weight of one stereoisomer of the compound and less than about 5% by weight of the other stereoisomers of the compound, or greater than about 97% by weight of one stereoisomer of the compound and less than about 3% by weight of the other stereoisomers of the compound. The compounds disclosed herein have chiral centers and can occur as individual enantiomers or diastereomers, and mixtures thereof. All such isomeric forms are included within the embodiments disclosed herein, including mixtures thereof.

[0022] The use of stereomerically pure forms of such compounds, as well as the use of mixtures of those forms, are encompassed by the embodiments disclosed herein. For example, mixtures comprising equal or unequal amounts of the enantiomers of a particular compound may be used in methods and compositions disclosed herein. These isomers may be asymmetrically synthesized or resolved using standard techniques such as chiral columns or chiral resolving agents. See, e.g., Jacques, J., et al., Enantiomers, Racemates and Resolutions (Wiley-Interscience, New York, 1981); Wilen, S. H., etal., Tetrahedron 33:2725 (1977); Eliel, E. L., Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, S. H., Tables of Resolving Agents and Optical Resolutions p. 268 (E.L. Eliel, Ed., Univ, of Notre Dame Press, Notre Dame, IN, 1972).

[0023] As used herein and unless otherwise indicated, the term “prodrug” means a compound that can hydrolyze, oxidize, or otherwise react under biological conditions (in vitro or in vivo) to provide an active compound, particularly a compound disclosed herein. Examples of prodrugs include, but are not limited to, derivatives and metabolites of a compound disclosed herein that include biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogues. In certain embodiments, prodrugs of compounds with carboxyl functional groups are the lower alkyl esters of the carboxylic acid. The carboxylate 5NAI-5002374383vlesters are conveniently formed by esterifying any of the carboxylic acid moieties present on the molecule. Prodrugs can typically be prepared using well-known methods, such as those described by Burger ’s Medicinal Chemistry and Drug Discovery 6thed. (Donald J. Abraham ed., 2001, Wiley) an Design and Application of Prodrugs (H. Bundgaard ed., 1985, Harwood Academic Publishers Gmfh).

[0024] “ Tautomers” refers to isomeric forms of a compound that are in equilibrium with each other. The concentrations of the isomeric forms will depend on the environment the compound is found in and may be different depending upon, for example, whether the compound is a solid or is in an organic or aqueous solution. For example, in aqueous solution, pyrazoles may exhibit the following isomeric forms, which are referred to as tautomers of each other:

[0025] Unless otherwise specified, the terms “solvate” and “solvated,” as used herein, refer to a solid form of a substance which contains solvent. The terms “hydrate” and “hydrated” refer to a solvate wherein the solvent comprises water. The terms “solvate” and “solvated,” as used herein, can also refer to a solvate of a salt, co-crystal, or molecular complex. The terms “hydrate” and “hydrated,” as used herein, can also refer to a hydrate of a salt, co-crystal, or molecular complex.

[0026] The term “isotopologue” of a compound described herein refers to a compound that can contain unnatural proportions of atomic isotopes at one or more of the atoms. For example, an isotopologue of Compounds 1 to 4 may be radiolabeled at one or more positions with radioactive isotopes, such as for example tritium (3H), and / or carbon-14 (14C), or may be isotopically enriched at one or more positions, such as with deuterium (2H), carbon-13 (13C), oxygen- 18 (18O) and / or nitrogen- 15 (15N). In certain embodiments, a compound described herein can be radiolabeled at one or more positions with radioactive isotopes, such as for example tritium (3H), and / or carbon-14 (14C), while also being isotopically enriched at one or more positions, such as with deuterium (2H), carbon- 13 (13C), oxygen- 18 (18O) and / or nitrogen-15 (15N).

[0027] All isotopic variations of Compounds 1 to 4, whether radioactive or not, are intended to be encompassed within the scope of the embodiments provided herein. In some embodiments, there are provided isotopologues of Compounds 1 to 4, for example, the isotopologues are deuterium, carbon-13, or nitrogen-15 enriched Compounds 1 to 4.6NAI-5002374383vl

[0028] With regard to the compounds provided herein, when a particular atomic position is designated as having deuterium or “D,” it is understood that the abundance of deuterium at that position is substantially greater than the natural abundance of deuterium, which is about 0.0156%. A position designated as having deuterium typically has a minimum isotopic enrichment factor of, in particular embodiments, at least 100 (1.56% deuterium incorporation), at least 500 (7.8% deuterium incorporation), at least 1000 (15.6% deuterium incorporation), at least 2000 (31.2% deuterium incorporation), at least 3000 (46.8% deuterium incorporation), at least 3500 (54.6% deuterium incorporation), at least 4000 (62.4% deuterium incorporation), at least 4500 (70.2% deuterium incorporation), at least 5000 (78% deuterium incorporation), at least 5500 (85.8% deuterium incorporation), at least 6000 (93.6% deuterium incorporation), at least 6089.7 (95% deuterium incorporation), at least 6217.9 (97% deuterium incorporation), at least 6346.2 (99% deuterium incorporation), or at least 6378.2 (99.5% deuterium incorporation) at each designated deuterium atom.

[0029] The isotopic enrichment and isotopic enrichment factor of the compounds provided herein can be determined using conventional analytical methods known to one of ordinary skill in the art, including mass spectrometry and nuclear magnetic resonance spectroscopy.

[0030] The term “treat” means decrease, suppress, attenuate, alleviate, diminish, arrest, or stabilize the development or progression of a disease / disorder (e.g., amyotrophic lateral sclerosis).

[0031] As used herein, and unless otherwise specified, the terms “prevent,” “preventing” and “prevention” refer to the prevention of the onset, recurrence or spread of a disease or disorder, or of one or more symptoms thereof. The terms “prevent,” “preventing” and “prevention” contemplate an action that occurs before a patient begins to suffer from the specified disease or disorder or symptoms thereof, which inhibits or reduces the severity of the disease or disorder.

[0032] As used herein, and unless otherwise indicated, the terms “manage,” “managing” and “management” encompass preventing the recurrence of the specified disease or disorder in a patient who has already suffered from the disease or disorder, or lengthening the time that a patient who has suffered from the disease or disorder remains in remission. The terms encompass modulating the threshold, development or duration of the disease or disorder, or changing the way that a patient responds to the disease or disorder.

[0033] As used herein, and unless otherwise specified, a “therapeutically effective amount” of a compound is an amount sufficient to provide a therapeutic benefit in the treatment or management of a disease or disorder, or to delay or minimize one or more symptoms associated 7NAI-5002374383vlwith the disease or disorder. A therapeutically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other therapies, that provides a therapeutic benefit in the treatment or management of the disease or disorder. The term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of disease or disorder, or enhances the therapeutic efficacy of another therapeutic agent.

[0034] Unless otherwise specified, the term “composition” as used herein is intended to encompass a product comprising the specified ingredient(s) (and in the specified amount(s), if indicated), as well as any product which results, directly or indirectly, from combination of the specified ingredient(s) in the specified amount(s).

[0035] A “pharmaceutically acceptable excipient, diluent or carrier,” refers to a substance that aids the administration of an active agent to a subject by for example by modifying the stability of an active agent or modifying the absorption by a subject upon administration. A pharmaceutically acceptable excipient typically has no significant adverse toxicological effect on the patient. Examples of pharmaceutically acceptable excipients include, for example bulking agents, buffers, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, fatty acid esters, hydroxy methylcellulose, polyvinyl pyrrolidine, and colors, and the like. One of skill in the art will recognize that other pharmaceutical excipients known in the art are useful in the present invention and include those listed in for example the Handbook of Pharmaceutical Excipients, Rowe R.C., Shesky P.J., and Quinn M.E., 6thEd., The Pharmaceutical Press, RPS Publishing (2009). The terms “bulking agent”, and “buffer” are used in accordance with the plain and ordinary meaning within the art.

[0036] As used herein, “administer” or “administration” refers to the act of physically delivering a substance as it exists outside the body into a subject. Administration includes all forms known in the art for delivering therapeutic agents, including but not limited to oral, topical, mucosal, injections, intradermal, intravenous, intramuscular delivery or other method of physical delivery described herein or known in the art (e.g., implantation of a slow-release device, such as a mini-osmotic pump to a subject; liposomal formulations; buccal; sublingual; palatal; gingival; nasal; vaginal; rectal; intra-arteriole; intraperitoneal; intraventricular; intracranial; or transdermal).

[0037] As used herein, “subject” or “patient” is an animal, typically a mammal, including a human, such as a human patient.

[0038] As used herein, and unless otherwise specified, the terms “about” and “approximately,” when used in connection with doses, amounts, or weight percents of 8NAI-5002374383vlingredients of a composition or a dosage form, mean a dose, amount, or weight percent that is recognized by one of ordinary skill in the art to provide a pharmacological effect equivalent to that obtained from the specified dose, amount, or weight percent. In certain embodiments, the terms “about” and “approximately,” when used in this context, contemplate a dose, amount, or weight percent within 39%, within 29%, within 15%, within 19%, or within 5%, of the specified dose, amount, or weight percent.

[0039] In certain embodiments, such as those referring to the location of a peak on a XRPD spectrum, “approximately” refers to a value within (e.g., ±) 0.2° 29, 0.1° 29, or 0.0° 29 of the named value. In some embodiments, the value of XRPD peak position may vary by up to ± 0.2 degrees 29 while still describing the particular XRPD peak. In one embodiment, the value of XRPD peak position may vary up to ± 0.1 degrees 29. In one embodiment, the value of XRPD peak position may vary up to ± 0.05 degrees 29.

[0040] Unless otherwise specified, to the extent that there is a discrepancy between a depicted chemical structure of a compound provided herein and a chemical name of a compound provided herein, the chemical structure shall control.2. Compounds

[0041] In certain embodiments, provided herein is (5R,6S)-10,ll-difhioro-12-((2-fhioro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide having the following formula:

[0042] In one embodiment, Compound 1 provided herein is a crystalline solid. In one embodiment, Compound 1 provided herein is Form A. In one embodiment, Compound 1 provided herein is Form B. In one embodiment, Compound 1 provided herein is Form C.

[0043] In one embodiment, Compound 1 provided herein is a solid form comprising a free base of Compound 1, characterized by an XRPD pattern comprising peaks at approximately 8.5, 15.1, and 18.3° 29. In one embodiment, the XRPD pattern further comprises peaks at approximately 9.2, 12.0, and 17.0° 29. In one embodiment, the XRPD pattern further comprises peaks at approximately 20.8, 22.0, 24.1, and 27.4° 29. In one embodiment, the XRPD pattern9NAI-5002374383vlcomprises peaks at approximately 8.5, 9.2, 10.7, 11.6, 12.0, 12.8, 15.1, 17.0, 18.3, 20.8, 22.0, 24.1, and 27.4° 29. In some such embodiments, Compound 1 is solid Form A. In one embodiment, solid Form A is characterized by an XRPD pattern comprising peaks at approximately 8.5, 15.1, and 18.3° 29. In one embodiment, solid Form A is characterized by an XRPD pattern comprising peaks at approximately 8.5, 9.2, 10.7, 11.6, 12.0, 12.8, 15.1, 17.0, 18.3, 20.8, 22.0, 24.1, and 27.4° 29. In one embodiment, the solid Form A comprising a free base of Compound 1 is an anhydrate.

[0044] In one embodiment, Compound 1 provided herein is a solid form comprising a free base of Compound 1, characterized by an XRPD pattern comprising peaks at approximately 8.4, 12.5, and 16.9° 29. In one embodiment, the XRPD pattern further comprises peaks at approximately 17.6, 17.9, and 18.1° 29. In one embodiment, the XRPD pattern further comprises peaks at approximately 20.4, 23.5, and 23.8° 29. In one embodiment, the XRPD pattern further comprises peaks at approximately 25.2, 27.1, and 29.2° 29. In one embodiment, the XRPD pattern comprises peaks at approximately 16.9, and 17.9° 29. In one embodiment, the XRPD pattern comprises peaks at approximately 16.9, 17.6, 17.9, and 18.1° 29. In one embodiment, the XRPD pattern comprises peaks at approximately 14.8, 14.9, and 15.3° 29. In one embodiment, the XRPD pattern comprises peaks at approximately 21.9, 23.5, and 23.8° 29. In one embodiment, the XRPD pattern comprises peaks at approximately 8.4, 9.0, 10.3, 11.5, 12.5, 14.8, 14.9, 15.3, 16.9, 17.6, 17.9, 18.1, 19.3, 19.9, 20.4, 21.9, 23.5, 23.8, 24.1, 24.9, 25.2, 25.6, 27.1, 28.5, 28.9, 29.2, 30.3, 31.7, 32.0, 32.4, 32.8, 35.7, and 36.7° 29. In some such embodiments, Compound 1 is solid Form B. In one embodiment, the solid Form B comprising a free base of Compound l isa solvate. In some such embodiments, Compound 1 is solid Form B. In one embodiment, solid Form B is characterized by an XRPD pattern comprising peaks at approximately 8.4, 12.5, and 16.9° 29. In one embodiment, solid Form B is characterized by an XRPD pattern comprising peaks at approximately 8.4, 9.9, 19.3, 11.5, 12.5, 14.8, 14.9, 15.3, 16.9, 17.6, 17.9, 18.1, 19.3, 19.9, 29.4, 21.9, 23.5, 23.8, 24.1, 24.9, 25.2, 25.6, 27.1, 28.5, 28.9, 29.2, 39.3, 31.7, 32.9, 32.4, 32.8, 35.7, and 36.7° 29. In one embodiment, the solid Form B comprising a free base of Compound 1 is an acetonitrile solvate.

[0045] In one embodiment, Compound 1 provided herein is a solid form comprising a free base of Compound 1, characterized by an XRPD pattern comprising peaks at approximately 8.3, 12.6, and 16.6° 29. In one embodiment, the XRPD pattern further comprises peaks at approximately 17.4, 18.1, and 18.4° 29. In one embodiment, the XRPD pattern further comprises peaks at approximately 29.7, 23.4, and 23.6° 29. In one embodiment, the XRPD pattern further comprises peaks at approximately 25.4, 26.9, 27.9, and 29.9° 29. In one 10NAI-5002374383vlembodiment, the XRPD pattern comprises peaks at approximately 16.6, 17.4, 18.1, and 18.4° 29. In one embodiment, the XRPD pattern comprises peaks at approximately 20.7, 21.1, 21.4, and 21.9° 29. In one embodiment, the XRPD pattern comprises peaks at approximately 23.4, 23.6, and 24.1° 29. In one embodiment, the XRPD pattern comprises peaks at approximately 24.8, 25.0, 25.4, 25.9, and 26.9° 29. In one embodiment, the XRPD pattern comprises peaks at approximately 27.9 and 28.4° 29. In one embodiment, the XRPD pattern comprises peaks at approximately 29.9, 31.0° 29. In one embodiment, the XRPD pattern comprises peaks at approximately 8.3, 9.1, 10.5, 11.5, 11.7, 12.6, 16.6, 17.4, 18.1, 18.4, 20.7, 21.1, 21.4, 21.9, 23.4, 23.6, 24.1, 24.8, 25.0, 25.4, 25.9, 26.9, 27.9, 28.4, 29.9, 31.0, 31.3, 31.7, and 32.7° 29. In some such embodiments, Compound 1 is solid Form C. In one embodiment, solid Form C is characterized by an XRPD pattern comprising peaks at approximately 8.3, 12.6, and 16.6° 29. In one embodiment, solid Form C is characterized by an XRPD pattern comprising peaks at approximately 8.3, 9.1, 10.5, 11.5, 11.7, 12.6, 16.6, 17.4, 18.1, 18.4, 20.7, 21.1, 21.4, 21.9, 23.4, 23.6, 24.1, 24.8, 25.0, 25.4, 25.9, 26.9, 27.9, 28.4, 29.9, 31.0, 31.3, 31.7, and 32.7° 29. In one embodiment, the solid Form C comprising a free base of Compound 1 is a solvate. In one embodiment, the solid Form C comprising a free base of Compound l is a methanol solvate.

[0046] In certain embodiments, provided herein is Compound 2. In certain embodiments, provided herein is pure Compound 2 or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, isotopologue, or prodrug thereof:

[0047] In certain embodiments, provided herein is Compound 3. In certain embodiments, provided herein is pure Compound 3 or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, isotopologue, or prodrug thereof:11NAI-5002374383vl3.

[0048] In certain embodiments, provided herein is Compound 4. In certain embodiments, provided herein is pure Compound 4 or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, isotopologue, or prodrug thereof:

[0049] In certain embodiments, the compound disclosed herein (e.g., Compound 1, Compound 2, Compound 3, or Compound 4) is the stereomerically pure compound or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, ester, isotopologue, or prodrug thereof. In certain embodiments, the compound according to Compound 1 to 4 is the stereomerically pure compound or a pharmaceutically acceptable salt thereof. In certain embodiments, the stereomerically pure compound comprises at least about 80% by weight of the designated stereoisomer and at most about 20% by weight of the other stereoisomer(s), at least about 90% by weight of the designated stereoisomer and at most about 10% by weight of the other stereoisomer(s), at least about 95% by weight of the designated stereoisomer and at most about 5% by weight of the other stereoisomer(s), at least about 96.6% by weight of the designated stereoisomer and at most about 3.4% by weight of the other stereoisomer(s), at least about 97% by weight of the designated stereoisomer and at most about 3% by weight of the other stereoisomer(s), at least about 99% by weight of the designated stereoisomer and at most about 1% by weight of the other stereoisomer(s), or at least about 99.9% by weight of the designated stereoisomer and at most about 0.1% by weight of the other stereoisomer(s). In12NAI-5002374383vlcertain embodiments, the weights are based upon total weight of the compound. Compounds 1 through 4 and their method of preparation have been described in U.S. Provisional Application No. 63 / 722,523, filed November 19, 2024; U.S. Provisional Application No.63 / 618,167, filed January 05, 2024, and International Application Number PCT / US2025 / 010070, filed January 2, 2025, the disclosures of each of which are incorporated by reference herein in their entirety.3. Formulations

[0050] In certain embodiments, the formulations provided herein are tablets comprising Compound 1 and a pharmaceutically acceptable excipient. Tablet formulations of Compound 1 have been described in Chinese priority application No. PCT / CN2024 / 133928 (filed November 22, 2024);US provisional application No. 63 / 744,073 (filed January 10, 2025); US provisional application No. 63 / 815,358 (filed May 30, 2025); US provisional application No.63 / 854,343 (filed July 30, 2025). All of the abovementioned applications are herein incorporated by reference in their entirety.

[0051] In certain embodiments, the tablet provided herein comprises Compound 1 in about 1% to about 10% by weight based on total weight of the tablet. In certain embodiments, the tablet provided herein comprises Compound 1 in about 2% to about 3% by weight based on total weight of the tablet. In certain embodiments, the tablet provided herein comprises Compound 1 in about 3% to about 4% by weight based on total weight of the tablet. In certain embodiments, the tablet provided herein comprises Compound 1 in about 4% to about 5% by weight based on total weight of the tablet. In certain embodiments, the tablet composition provided herein comprises Compound 1 in about 1%, about 2%, about 3%, about 4%, or about 5% by weight based on total weight of the tablet. In certain embodiments, the tablet provided herein comprises Compound 1 in about 5% by weight based on total weight of the tablet.

[0052] In certain embodiments, the tablet provided herein comprises Compound 1 and one or more excipients selected from a binder, a diluent, a disintegrant, a flow agent, a surfactant, a glidant and a lubricant. In certain embodiments, the tablet provided herein comprises Compound 1 and one or more excipients selected from a diluent, a disintegrant, a glidant, and a lubricant.

[0053] In certain embodiments, the binder is povidone. In certain embodiments, the binder is present in an amount from about 10% to 50% by weight based on total weight of the tablet.

[0054] In certain embodiments, the diluent is microcrystalline cellulose, lactose monohydrate, or pregelatinized starch, mannitol, anhydrous dibasic calcium phosphate, or a mixture thereof. In certain embodiments, the diluent is present in an amount from about 10 to 13NAI-5002374383vl65% by weight based on total weight of the tablet. In certain embodiments, the diluent is present in an amount from about 10 to 50% by weight based on total weight of the tablet. In certain embodiments, the diluent is present in an amount from about 14% to 45% by weight based on total weight of the tablet. In certain embodiments, the diluent is present in an amount from about 20% to 45% by weight based on total weight of the tablet. In certain embodiments, the diluent is present in an amount from about 30% to 45% by weight based on total weight of the tablet. In certain embodiments, the diluent is present in an amount from about 42% to 46% by weight based on total weight of the tablet. In certain embodiments, the diluent is present in an amount from about 22% to 26% by weight based on total weight of the tablet. In certain embodiments, the diluent is present in an amount from about 13% to 17% by weight based on total weight of the tablet. In certain embodiments, the diluent is present in an amount of about 15%, about 20%, about 23%, about 24%, about 30%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 44.2%, about 44.4%, about 62%, about 63%, about 64%, or about 65% by weight based on total weight of the tablet. In certain embodiments, the diluent is present in an amount of about 15%, about 24%, or about 44.2% by weight based on total weight of the tablet. In certain embodiments, the diluent is present in an amount of about 15%, about 24%, or about 44.4% by weight based on total weight of the tablet. In certain embodiments, the diluent is present in an amount of about 15%, about 24%, or about 44% by weight based on total weight of the tablet. In certain embodiments, the diluent is mannitol, which is present in an amount of about 30% by weight based on total weight of the tablet. In certain embodiments, the diluent is anhydrous dibasic calcium phosphate, which is present in an amount of about 30% by weight based on total weight of the tablet. In certain embodiments, the diluent is microcrystalline cellulose, which is present in an amount of about 44.4% by weight based on total weight of the tablet. In certain embodiments, the diluent is lactose monohydrate, which is present in an amount of about 24% by weight based on total weight of the tablet. In certain embodiments, the diluent is pregelatinized starch, which is present in an amount of about 15% by weight based on total weight of the tablet.

[0055] In certain embodiments, the disintegrant is present in an amount from about 2 to 15% by weight based on total weight of the tablet. In certain embodiments, the disintegrant is present in an amount from about 8 to 12% by weight based on total weight of the tablet. In certain embodiments, the disintegrant is present in an amount from about 5 to 10% by weight based on total weight of the tablet. In certain embodiments, the disintegrant is present in an amount from about 5 to 7% by weight based on total weight of the tablet. In certain embodiments, the disintegrant is present in an amount of about 5%, about 6%, about 7%, about 14NAI-5002374383vl8%, about 9%, or about 10% by weight based on total weight of the tablet. In certain embodiments, the disintegrant is present in an amount of about 5% by weight based on total weight of the tablet. In certain embodiments, the disintegrant is present in an amount of about 10% by weight based on total weight of the tablet. In certain embodiments, the disintegrant is croscarmellose sodium, which is present in an amount of about 5% by weight based on total weight of the tablet. In certain embodiments, the disintegrant is crospovidone, which is present in an amount of about 10% by weight based on total weight of the tablet.

[0056] In certain embodiments, the flow agent is silicified microcrystalline cellulose. In certain embodiments, the flow agent is present in an amount from about 10% to 50% by weight based on total weight of the tablet.

[0057] In certain embodiments, the surfactant is sodium lauryl sulfate. In certain embodiments, the surfactant is present in an amount from about 1% to 10% by weight based on total weight of the tablet.

[0058] In certain embodiments, the glidant is colloidal silicon dioxide. In certain embodiments, the glidant is present in an amount from about 0.01% to 1% by weight based on total weight of the tablet. In certain embodiments, the glidant is present in an amount from about 0.1% to 0.6% by weight based on total weight of the tablet. In certain embodiments, the glidant is present in an amount from about 0.2% to 0.6% by weight based on total weight of the tablet. In certain embodiments, the glidant is present in an amount from about 0.3% to 0.7% by weight based on total weight of the tablet. In certain embodiments, the glidant is present in an amount from about 0.4% to 0.5% by weight based on total weight of the tablet. In certain embodiments, the glidant is present in an amount of about 0.5% by weight based on total weight of the tablet. In certain embodiments, the glidant is colloidal silicon dioxide, which is present in an amount of about 0.5% by weight based on total weight of the tablet.

[0059] In certain embodiments, the lubricant is magnesium stearate or sodium stearyl fumarate. In certain embodiments, the lubricant is present in an amount from about 0.05% to 5% by weight based on total weight of the tablet. In certain embodiments, the lubricant is present in an amount from about 0.1% to 5% by weight based on total weight of the tablet. In certain embodiments, the lubricant is present in an amount from about 0.1% to 2% by weight based on total weight of the tablet. In certain embodiments, the lubricant is present in an amount from about 0.1% to 1% by weight based on total weight of the tablet. In certain embodiments, the lubricant is present in an amount from about 0.05% to 0.7% by weight based on total weight of the tablet. In certain embodiments, the lubricant is present in an amount of about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.1%, about 0.2%, about 0.3%,15NAI-5002374383vlabout 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2%, about 3%, about 4%, about 5% by weight based on total weight of the tablet. In certain embodiments, the lubricant is present in an amount of about 0.5% by weight based on total weight of the tablet. In certain embodiments, the lubricant is magnesium stearate, which is present in an amount of about 0.1% by weight based on total weight of the tablet. In certain embodiments, the lubricant is magnesium stearate, which is present in an amount of about 0.5% by weight based on total weight of the tablet. In certain embodiments, the lubricant is magnesium stearate, which is present in an amount of about 1% by weight based on total weight of the tablet. In certain embodiments, the lubricant is sodium stearyl fumarate, which is present in an amount of about 1% by weight based on total weight of the tablet.

[0060] In certain embodiments, the tablet provided herein comprises Compound 1, microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate. In certain embodiments, the tablet provided herein comprises Compound 1, mannitol, anhydrous dibasic calcium phosphate, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and sodium stearyl fumarate.

[0061] In certain embodiments, the tablet provided herein comprises Compound 1, microcrystalline cellulose, lactose monohydrate, crospovidone, colloidal silicon dioxide, and magnesium stearate. In certain embodiments, the tablet provided herein comprises Compound 1, microcrystalline cellulose, lactose monohydrate, pregelatinized starch, crospovidone, colloidal silicon dioxide, and magnesium stearate.

[0062] In certain embodiments, the tablet provided herein comprises about 1% to about 10% Compound 1, about 42% to about 46% microcrystalline cellulose, about 22% to about 26% lactose monohydrate, about 13% to about 17% pregelatinized starch, about 8% to about 12% crospovidone, about 0.3% to about 0.7% colloidal silicon dioxide, and about 0.05% to about 0.7% magnesium stearate, by weight based on total weight of the tablet.

[0063] In certain embodiments, the tablet provided herein comprises about 5% Compound 1, about 44.4% microcrystalline cellulose, about 24% lactose monohydrate, about 15% pregelatinized starch, about 10% crospovidone, about 0.5% colloidal silicon dioxide, and about 0.1% magnesium stearate, where the percentages are by weight based on total weight of the tablet. In some such embodiments, the tablet further comprising 0.5% magnesium stearate. In some such embodiments, the tablet further comprises 0.5% colloidal silicon dioxide.

[0064] In certain embodiments, the tablet provided herein comprises about 5% Compound 1, about 44.4% microcrystalline cellulose, about 24% lactose monohydrate, about 15% pregelatinized starch, about 10% crospovidone, about 1% colloidal silicon dioxide, and about 16NAI-5002374383vl0.6% magnesium stearate, where the percentages are by weight based on total weight of the tablet.

[0065] In certain embodiments, the tablet provided herein comprises intragranular components and extragranular components. In certain embodiments, the tablet provided herein comprises intragranular components comprising about 5% Compound 1, about 44.4% microcrystalline cellulose, about 24% lactose monohydrate, about 15% pregelatinized starch, about 10% crospovidone; about 0.5% colloidal silicon dioxide, and about 0.1% magnesium stearate; and extragranular components comprising about 0.5% magnesium stearate and about 0.5% colloidal silicon dioxide.

[0066] In certain embodiments, each tablet weighs about 1 mg to about 200 mg. In certain embodiments, each tablet weighs about 1 mg to about 100 mg. In certain embodiments, each tablet weighs about 1 mg to about 80 mg. In certain embodiments, each tablet weighs about 1 mg to about 60 mg. In certain embodiments, each tablet weighs about 1 mg to about 40 mg. In certain embodiments, each tablet weighs about 1 mg to about 20 mg. In certain embodiments, each tablet weighs about 1 mg to about 10 mg. In certain embodiments, each tablet weighs about 1 mg, 1.5 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, or 20 mg. In certain embodiments, each tablet weighs about 1 mg, 3 mg, 4 mg, 5 mg, 10 mg, 20 mg, about 80 mg, or about 200 mg. In certain embodiments, each tablet weighs about 20 mg. In certain embodiments, each tablet weighs about 80 mg. In certain embodiments, each tablet weighs about 200 mg.

[0067] In certain embodiments, each tablet comprises Compound 1 at a weight of about 1 mg to about 200 mg. In certain embodiments, each tablet comprises Compound 1 at a weight of about 1 mg to about 100 mg. In certain embodiments, each tablet comprises about 1 mg to about 80 mg of Compound 1. In certain embodiments, each tablet comprises about 1 mg to about 60 mg of Compound 1. In certain embodiments, each tablet comprises about 1 mg to about 40 mg of Compound 1. In certain embodiments, each tablet comprises about 1 mg to about 20 mg of Compound 1. In certain embodiments, each tablet comprises about 1 mg to about 10 mg of Compound 1. In certain embodiments, each tablet comprises about 1 mg, about 1.5 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 22 mg, about 30 mg, about 37 mg, about 40 mg, or about 45 mg of Compound 1. In certain embodiments, each tablet comprises about 2 mg, about 4 mg, about 8 mg, about 10 mg, about 15 mg, about 22 mg,17NAI-5002374383vlabout 30 mg, about 37 mg, about 40 mg, or about 45 mg of Compound 1. In certain embodiments, each tablet comprises about 2 mg to about 200 mg of Compound 1. In certain embodiments, each tablet comprises about 2 mg to about 100 mg of Compound 1. In certain embodiments, each tablet comprises about 2 mg to about 45 mg of Compound 1. In certain embodiments, each tablet comprises about 4 mg to about 45 mg of Compound 1.

[0068] In certain embodiments, each tablet has a diameter of about 1 mm to 10 mm. In certain embodiments, each tablet has a diameter of about 2 mm to 8 mm. In certain embodiments, each tablet has a diameter of about 3 mm to 5 mm. In certain embodiments, each tablet has a diameter of about 1 mm, 2 mm, 3 mm, about 4 mm, about 5 mm, about 6 mm, about 7 mm, about 8 mm, about 9 mm, or about 10 mm. In certain embodiments, each tablet has a diameter of about 3 mm. In certain embodiments, each tablet has a diameter of about 5.5 mm. In certain embodiments, each tablet has a diameter of about 5 mm. In certain embodiments, each tablet has a diameter of about 8 mm.

[0069] In certain embodiments, the tablet comprises a coating. In certain embodiments, the coating is Opadry. In certain embodiments, the coating is Opadry yellow. In certain embodiments, the coating provides a weight gain of about 1 to 5%. In certain embodiments, the coating provides a weight gain of about 2 to 3%. In certain embodiments, the coating provides a weight gain of about 1%, 2%, or 3%. In certain embodiments, the coating provides a weight gain of about 3%.4. Method of Use

[0070] Provided herein is a method of treating amyotrophic lateral sclerosis (ALS) comprising administering a therapeutically effective amount of the compounds disclosed herein (e.g., Compound 1, Compound 2, Compound 3, and Compound 4). In one embodiment, provided herein is a method of treating amyotrophic lateral sclerosis comprising administering a therapeutically effective amount of (5R,6S)-10,ll-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide or a pharmaceutically acceptable salt or solid form thereof (Compound 1), to a patient having amyotrophic lateral sclerosis. In one embodiment, provided herein is Compound 1 provided herein for use in a method of treating amyotrophic lateral sclerosis, wherein the method comprises administering Compound 1 to a patient having amyotrophic lateral sclerosis.

[0071] In one embodiment, provided herein is a method of treating amyotrophic lateral sclerosis, comprising administering to a patient having amyotrophic lateral sclerosis a tablet formulation comprising Compound 1. In one embodiment, provided herein is a method of 18NAI-5002374383vltreating amyotrophic lateral sclerosis, wherein the method comprises administering to a patient having amyotrophic lateral sclerosis a tablet formulation comprising about 1% to about 10% of (5R,6S)-10,ll -difluoro- 12-((2-fluoro-4-iodophenyl)amino)-5 , 6-dihy droxy-4, 5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide or a pharmaceutically acceptable salt or solid form thereof (Compound 1), about 42% to about 46% microcrystalline cellulose, about 22% to about 26% lactose monohydrate, about 13% to about 17% pregelatinized starch, about 8% to about 12% crospovidone, about 0.3% to about 0.7% colloidal silicon dioxide, and about 0.05% to about 0.7% magnesium stearate, where the percentages are by weight based on total weight of the tablet.

[0072] In one embodiment, provided herein is a tablet formulation of Compound 1 provided herein for use in a method of treating amyotrophic lateral sclerosis, wherein the method comprises administering said tablet formulation to a patient. In one embodiment, provided herein is a tablet formulation of Compound 1 provided herein for use in a method of treating amyotrophic lateral sclerosis, wherein the method comprises administering to a patient having amyotrophic lateral sclerosis a tablet formulation comprising about 1% to about 10% of (5R, 6S)-10, 11 -difluoro- 12-((2 -fluoro-4-iodophenyl)amino)-5,6-dihydroxy -4,5,6, 7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide or a pharmaceutically acceptable salt or solid form thereof (Compound 1), about 42% to about 46% microcrystalline cellulose, about 22% to about 26% lactose monohydrate, about 13% to about 17% pregelatinized starch, about 8% to about 12% crospovidone, about 0.3% to about 0.7% colloidal silicon dioxide, and about 0.05% to about 0.7% magnesium stearate, where the percentages are by weight based on total weight of the tablet.

[0073] In one embodiment, provided herein is a method of preventing amyotrophic lateral sclerosis, comprising administering a therapeutically effective amount of the compounds disclosed herein (e.g., Compound 1, Compound 2, Compound 3, and Compound 4). In one embodiment, provided herein is a method of preventing amyotrophic lateral sclerosis, which comprises administering to a patient a therapeutically effective amount of Compound 1 provided herein. In one embodiment, provided herein is Compound 1 provided herein for use in a method of preventing amyotrophic lateral sclerosis, wherein the method comprises administering Compound 1 provided herein to a patient.

[0074] In one embodiment, provided herein is a method of preventing amyotrophic lateral sclerosis, which comprises administering to a patient a tablet formulation of Compound 1 provided herein. In one embodiment, provided herein is a tablet formulation of Compound 1 provided herein for use in a method of preventing amyotrophic lateral sclerosis, wherein the 19NAI-5002374383vlmethod comprises administering a tablet formulation of Compound 1 provided herein to a patient.

[0075] In one embodiment, provided herein is a method of managing amyotrophic lateral sclerosis, which comprises administering a therapeutically effective amount of the compounds disclosed herein (e.g., Compound 1, Compound 2, Compound 3, and Compound 4). In one embodiment, provided herein is a method of managing amyotrophic lateral sclerosis, which comprises administering to a patient a therapeutically effective amount of Compound 1 provided herein. In one embodiment, provided herein is Compound 1 provided herein for use in a method of managing amyotrophic lateral sclerosis, wherein the method comprises administering Compound 1 provided herein to a patient.

[0076] In one embodiment, provided herein is a method of managing amyotrophic lateral sclerosis, which comprises administering to a patient a tablet formulation of Compound 1 provided herein. In one embodiment, provided herein is a tablet formulation of Compound 1 provided herein for use in a method of managing amyotrophic lateral sclerosis, wherein the method comprises administering a tablet formulation of Compound 1 provided herein to a patient.

[0077] In a particular embodiment, the tablet formulation of Compound 1 comprises about 1% to about 10% of (5R,6S)-10,ll-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-di oxide or a pharmaceutically acceptable salt or solid form thereof (Compound 1), about 42% to about 46% microcrystalline cellulose, about 22% to about 26% lactose monohydrate, about 13% to about 17% pregelatinized starch, about 8% to about 12% crospovidone, about 0.3% to about 0.7% colloidal silicon dioxide, and about 0.05% to about 0.7% magnesium stearate, where the percentages are by weight based on total weight of the tablet.

[0078] In a particular embodiment, the tablet formulation of Compound 1 comprises about 1% to about 10% of (5R,6S)-10,ll-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-di oxide or a pharmaceutically acceptable salt or solid form thereof (Compound 1), about 42% to about 46% microcrystalline cellulose, about 22% to about 26% lactose monohydrate, about 13% to about 17% pregelatinized starch, about 8% to about 12% crospovidone, about 0.3% to about 0.7% colloidal silicon dioxide, and about 0.05% to about 0.7% magnesium stearate, where the percentages are by weight based on total weight of the tablet.

[0079] In one embodiment, the methods described herein comprise the step of administering to a patient a therapeutically effective amount of the compounds disclosed herein e.g.,20NAI-5002374383vlCompound 1, Compound 2, Compound 3, and Compound 4), wherein the administration reduces a symptom associated with amyotrophic lateral sclerosis, thereby treating the patient.

[0080] In one embodiment, the methods described herein comprise the step of administering to a patient a therapeutically effective amount of Compound 1 or a tablet formulation of Compound 1 disclosed herein, wherein the administration reduces a symptom associated with amyotrophic lateral sclerosis, thereby treating the patient.

[0081] The methods provided herein are based, in part, on the discovery that the level of neurofilament light chain (NfL) in the blood and cerebrospinal fluid (CSF) at diagnosis correlate with the speed and severity of ALS progression, indicating that it may be a prognostic biomarker for ALS. Neurofilament light chain (NfL) is a member of a family of proteins called neurofilaments that contribute to the structure of neurons in the brain and spinal cord. Research has shown that when neurons experience injury or damage, these proteins are shed and find their way into the cerebrospinal fluid (CSF) and bloodstream. While even healthy neurons shed a certain amount of NfL, elevated levels of the protein in blood or CSF are associated with several conditions that affect the central nervous system (See, the ALS Development Therapy Institute, August 28, 2023, https: / / www.als.net / news / neurofilament-light-chain / ). While all people with ALS appear to have some degree of elevated NfL in earlier stages of the disease, those with higher NfL levels early on have been found to experience faster disease progression than those with lower NfL levels.

[0082] In some embodiments of the methods described herein, the methods comprise monitoring the blood or plasma level of neurofilament light chain (NfL) in a patient. In some embodiments of the methods described herein, a reduction of the blood or plasma level of NfL in a patient correlates with efficacy. In some embodiments of the methods described herein, Compound 1 reduces the blood or plasma level of neurofilament light chain (NfL) in a patient. In some such embodiments, the reduction of the blood or plasma level of NfL in the patient is about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95% compared to the blood or plasma level of NfL before treatment. For the purpose of monitoring NfL, blood or plasma levels can be used interchangeably.

[0083] In some embodiments of the methods described herein, the methods comprise monitoring inflammatory markers in a patient. Inflammatory markers include, but are not limited to IFN-y, IL-ip, IL-2, IL-4, IL-6, IL- 10, IL-23, IL-12p70, IL- 17 A, TNF-a. In some21NAI-5002374383vlsuch embodiments, the inflammatory markers may be evaluated from serum, and / or plasma, and / or cell culture supernatant, and / or CSF, and / or urine samples.5. Pharmaceutical Composition

[0084] Provided herein are pharmaceutical compositions. The pharmaceutical compositions provided herein contain therapeutically effective amounts of the compounds provided herein (e.g., Compound 1, Compound 2, Compound 3, and Compound 4) and optionally a pharmaceutically acceptable carrier, diluent, or excipient. In certain embodiments, the pharmaceutical compositions provided herein contain therapeutically effective amounts of Compound 1 provided herein and optionally a pharmaceutically acceptable carrier, diluent, or excipient.

[0085] In some particular embodiments, the pharmaceutical compositions provided herein contain the tablet formulations described herein in Section 3.

[0086] The compounds provided herein can be formulated into suitable pharmaceutical preparations such as solutions, suspensions, tablets, dispersible tablets, pills, capsules, powders, sustained release formulations or elixirs, for oral administration or in sterile solutions or suspensions for ophthalmic or parenteral administration, as well as transdermal patch preparation and dry powder inhalers. Typically, the compounds provided herein described above are formulated into pharmaceutical compositions using techniques and procedures well known in the art (see, e.g., Ansel Introduction to Pharmaceutical Dosage Forms, Seventh Edition 1999).

[0087] In another embodiment, the compounds provided herein can be formulated into dosage forms for oral administration, e.g., a tablet or capsule. In some such embodiments, the compounds provided herein are formulated into oral dosage forms containing about 2 mg, about 4 mg, about 8 mg, about 10 mg, about 15 mg, about 22 mg, about 30 mg, about 37 mg, about 40 mg, or about 45 mg of Compound 1. In one particular embodiment, Compound 1 provided herein is formulated into an oral dosage form that, upon oral administration of about 2 mg, about 4 mg, about 8 mg, about 15 mg, about 22 mg, about 30 mg, about 37 mg, about 40 mg, or about 45 mg of Compound 1, treats, prevents, or ameliorates one or more of the symptoms and / or progression of disorders in a subject, such as amyotrophic lateral sclerosis.

[0088] In one particular embodiment, the compounds provided herein can be formulated into capsules. In some such embodiments, the compounds provided herein are formulated into 2 mg, 4 mg, or 15 mg capsules. In some such embodiments, Compound 1 provided herein is formulated into 2 mg, 4 mg, or 15 mg capsules. In one particular embodiment, Compound 1 provided herein is formulated into 15 mg capsules. In the compositions, effective 22NAI-5002374383vlconcentrations of the compounds provided herein are mixed with a suitable pharmaceutical carrier or vehicle. In certain embodiments, the concentrations of the compounds provided herein in the compositions are effective for delivery of an amount, upon administration, that treats, prevents, or ameliorates one or more of the symptoms and / or progression of disorders in a subject, such as amyotrophic lateral sclerosis.

[0089] Typically, the compositions are formulated for single dosage administration. To formulate a composition, the weight fraction of compound is dissolved, suspended, dispersed, or otherwise mixed in a selected vehicle at an effective concentration such that the treated condition is relieved or ameliorated. Pharmaceutical carriers or vehicles suitable for administration of the compounds provided herein include any such carriers known to those skilled in the art to be suitable for the particular mode of administration.

[0090] The active compound is included in the pharmaceutically acceptable carrier in an amount sufficient to exert a therapeutically useful effect in the absence of undesirable side effects on the patient treated. The therapeutically effective concentration may be determined empirically by testing the compounds in in vitro and in vivo systems described herein and then extrapolated therefrom for dosages for humans.

[0091] The concentration of active compound in the pharmaceutical composition will depend on absorption, tissue distribution, inactivation, metabolism and excretion rates of the active compound, the physicochemical characteristics of the compound, the dosage schedule, and amount administered as well as other factors known to those of skill in the art. For example, the amount that is delivered is sufficient to ameliorate one or more of the symptoms of disease disclosed herein.

[0092] The pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages. The pharmaceutical composition will include a conventional pharmaceutical carrier or excipient and a compound according to the invention as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc.

[0093] Exemplary parenteral administration forms include solutions or suspensions of active compounds in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired.

[0094] Suitable pharmaceutical carriers include inert diluents or fillers, water, and various organic solvents. The pharmaceutical compositions may, if desired, contain additional ingredients such as flavorings, binders, excipients, and the like. Thus, for oral administration, tablets containing various excipients, such as citric acid may be employed together with various 23NAI-5002374383vldisintegrants such as starch, alginic acid and certain complex silicates and with binding agents such as sucrose, gelatin, and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes. Solid compositions of a similar type may also be employed in soft and hard-filled gelatin capsules. In one particular embodiment, Compound 1 is administered in a tablet formulation. In some such embodiments, Compound 1 is administered in a tablet formulation as provided in Section 3.

[0095] Preferred materials, therefore, include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration, the active compound therein may be combined with various sweetening or flavoring agents, coloring matters or dyes and, if desired, emulsifying agents or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin, or combinations thereof. Methods of preparing various pharmaceutical compositions with a specific amount of active compound are known, or will be apparent, to those skilled in this art. For example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Ester, Pa., 18th Edition (1990).

[0096] In certain embodiments, the effective amount of the compounds in the pharmaceutical composition may be at a level that will exercise the desired effect; for example, about 0.001 mg / kg of a subject’s body weight to about 100 mg / kg of a subject’s body weight in unit dosage for both oral and parenteral administration.

[0097] In one embodiment, a therapeutically effective amount of the compounds or tablet formulation of Compound 1 provided herein generally is in the range of about 0.001 mg / kg / day to about 100 mg / kg / day. In aspects of this embodiment, an effective amount of the compounds or tablet formulation of Compound 1 provided herein may be, e.g., at least 0.001 mg / kg / day, at least 0.01 mg / kg / day, at least 0.1 mg / kg / day, at least 1.0 mg / kg / day, at least 5.0 mg / kg / day, at least 10 mg / kg / day, at least 15 mg / kg / day, at least 20 mg / kg / day, at least 25 mg / kg / day, at least 30 mg / kg / day, at least 35 mg / kg / day, at least 40 mg / kg / day, at least 45 mg / kg / day, or at least 50 mg / kg / day. In other aspects of this embodiment, an effective amount of the compounds or tablet formulation of Compound 1 provided herein may be in the range of, e.g., about 0.001 mg / kg / day to about 10 mg / kg / day, about 0.001 mg / kg / day to about 15 mg / kg / day, about 0.001 mg / kg / day to about 20 mg / kg / day, about 0.001 mg / kg / day to about 25 mg / kg / day, about 0.001 mg / kg / day to about 30 mg / kg / day, about 0.001 mg / kg / day to about 35 mg / kg / day, about 0.001 mg / kg / day to about 40 mg / kg / day, about 0.001 mg / kg / day to about 45 mg / kg / day, about 0.001 mg / kg / day to about 50 mg / kg / day, about 0.001 mg / kg / day to about 75 mg / kg / day, or about 24NAI-5002374383vl0.001 mg / kg / day to about 100 mg / kg / day. In yet other aspects of this embodiment, an effective amount of the compounds or tablet formulation of Compound 1 provided herein may be in the range of, e.g., about 0.01 mg / kg / day to about 10 mg / kg / day, about 0.01 mg / kg / day to about 15 mg / kg / day, about 0.01 mg / kg / day to about 20 mg / kg / day, about 0.01 mg / kg / day to about 25 mg / kg / day, about 0.01 mg / kg / day to about 30 mg / kg / day, about 0.01 mg / kg / day to about 35 mg / kg / day, about 0.01 mg / kg / day to about 40 mg / kg / day, about 0.01 mg / kg / day to about 45 mg / kg / day, about 0.01 mg / kg / day to about 50 mg / kg / day, about 0.01 mg / kg / day to about 75 mg / kg / day, or about 0.01 mg / kg / day to about 100 mg / kg / day. In still other aspects of this embodiment, an effective amount of the compounds or tablet formulation of Compound 1 provided herein may be in the range of, e.g., about 0.1 mg / kg / day to about 10 mg / kg / day, about 0.1 mg / kg / day to about 15 mg / kg / day, about 0.1 mg / kg / day to about 20 mg / kg / day, about 0.1 mg / kg / day to about 25 mg / kg / day, about 0.1 mg / kg / day to about 30 mg / kg / day, about 0.1 mg / kg / day to about 35 mg / kg / day, about 0.1 mg / kg / day to about 40 mg / kg / day, about 0.1 mg / kg / day to about 45 mg / kg / day, about 0.1 mg / kg / day to about 50 mg / kg / day, about 0.1 mg / kg / day to about 75 mg / kg / day, or about 0.1 mg / kg / day to about 100 mg / kg / day.

[0098] In other aspects of this embodiment, an effective amount of the compounds or tablet formulation of Compound 1 provided herein may be in the range of, e.g., about 1 mg / kg / day to about 10 mg / kg / day, about 1 mg / kg / day to about 15 mg / kg / day, about 1 mg / kg / day to about 20 mg / kg / day, about 1 mg / kg / day to about 25 mg / kg / day, about 1 mg / kg / day to about 30 mg / kg / day, about 1 mg / kg / day to about 35 mg / kg / day, about 1 mg / kg / day to about 40 mg / kg / day, about 1 mg / kg / day to about 45 mg / kg / day, about 1 mg / kg / day to about 50 mg / kg / day, about 1 mg / kg / day to about 75 mg / kg / day, or about 1 mg / kg / day to about 100 mg / kg / day. In yet other aspects of this embodiment, an effective amount of the compounds provided herein may be in the range of, e.g., about 5 mg / kg / day to about 10 mg / kg / day, about 5 mg / kg / day to about 15 mg / kg / day, about 5 mg / kg / day to about 20 mg / kg / day, about 5 mg / kg / day to about 25 mg / kg / day, about 5 mg / kg / day to about 30 mg / kg / day, about 5 mg / kg / day to about 35 mg / kg / day, about 5 mg / kg / day to about 40 mg / kg / day, about 5 mg / kg / day to about 45 mg / kg / day, about 5 mg / kg / day to about 50 mg / kg / day, about 5 mg / kg / day to about 75 mg / kg / day, or about 5 mg / kg / day to about 100 mg / kg / day.

[0099] The dose of the compounds provided herein to be administered to a subject is rather widely variable and can be subject to the judgment of a health-care practitioner. In any given case, the amount of the compounds administered will depend on such factors as the solubility of the active component, the formulation used and the route of administration. In one25NAI-5002374383vlembodiment, application of a topical concentration provides intracellular exposures or concentrations of about 0.01 - 10 pM.

[0100] The administered dose can also be expressed in units other than mg / kg / day. For example, doses for parenteral administration can be expressed as mg / m2 / day. One of ordinary skill in the art would readily know how to convert doses from mg / kg / day to mg / m2 / day given either the height or weight of a subject or both. For example, a dose of 1 mg / kg / day for a 65 kg human is approximately equal to 38 mg / m2 / day.

[0101] In some embodiments, an effective dose of the compounds or a tablet formulation of Compound 1 provided herein can be administered once daily (QD or qd) or divided into multiple daily. In addition, the administration can be continuous (i.e., daily for consecutive days or every day), intermittent, e.g., in cycles (i.e., including days, weeks, or months of rest without drug). Cycling therapy can reduce the development of resistance, avoid or reduce the side effects, and / or improve the efficacy of the treatment.

[0102] As used herein, the term “daily” is intended to mean that a therapeutic compound is administered once or more than once each day, for example, for a period of time.

[0103] In one embodiment, the pharmaceutical composition of the compounds or tablet formulation of Compound 1 provided herein is administered in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or greater than 40 cycles. In certain embodiments, the pharmaceutical composition of the compounds or tablet formulation of Compound 1 provided herein is administered for 1 to 25 cycles. In one embodiment, the median number of cycles administered in a group of patients is about 1. In one embodiment, the median number of cycles administered in a group of patients is about 2. In one embodiment, the median number of cycles administered in a group of patients is about 3. In one embodiment, the median number of cycles administered in a group of patients is about 4.

[0104] In certain embodiments, treatment cycles comprise multiple doses of the pharmaceutical composition of the compounds provided herein is administered to a patient in need thereof over multiple days (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or greater than 14 days), optionally followed by treatment dosing holidays (e.g, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or greater than 28 days).

[0105] In certain embodiments, the pharmaceutical composition of the compounds provided herein are administered in one or more 28-day cycles in the methods described herein. In certain embodiments, the pharmaceutical composition of the compounds provided herein are administered in a 28-day cycle in the methods described herein.26NAI-5002374383vl

[0106] In certain embodiments, the pharmaceutical composition of the compounds provided herein are administered orally in the methods described herein. In certain embodiments, the pharmaceutical composition of the compounds provided herein is administered with food or without food. In another embodiment, the pharmaceutical composition of the compounds provided herein is dispersed in water or juice (e.g., apple juice or orange juice) and administered orally as a suspension.

[0107] In one embodiment, the compounds provided herein can also be administered intradermally, intramuscularly, intraperitoneally, percutaneously, intravenously, subcutaneously, intranasally, epidurally, sublingually, intracerebrally, intravaginally, transdermally, rectally, mucosally, by inhalation, or topically to the ears, nose, eyes, or skin. The mode of administration is left to the discretion of the healthcare practitioner and can depend in-part upon the site of the medical condition.

[0108] The compounds disclosed herein may be administered as a sole therapy. The compounds disclosed herein may also be administered in combination with another therapy or therapies. In some embodiments, the compounds disclosed herein may also be administered in combination with another pharmaceutical agent with activity against amyotrophic lateral sclerosis.

[0109] Other therapies include, but are not limited to, administration of other therapeutic agents, radiation therapy, or both.

[0110] In instances where the compound described herein is administered with other therapeutic agents, the compound described herein need not be administered in the same pharmaceutical composition as other therapeutic agents, and may be because of different physical and chemical characteristics, be administered by a different route. For example, the compound or composition may be administered orally to generate and maintain good blood levels thereof, while the other therapeutic agent may be administered intravenously. The determination of the mode of administration and the advisability of administration, where possible, in the same pharmaceutical composition, is well within the knowledge of the skilled clinician. The initial administration can be made according to established protocols known in the art, and then, based upon the observed effects, the dosage, modes of administration and times of administration can be modified by the skilled clinician. The particular choice of compound (and where appropriate, other therapeutic agent and / or radiation) will depend upon the diagnosis of the attending physicians and their judgment of the condition of the patient and the appropriate treatment protocol. Other therapeutic agents may include chemotherapeutic27NAI-5002374383vlagents, such as anti -tumor substances. Such conjoint treatment may be achieved by way of the simultaneous, sequential, or separate dosing of the individual components of treatment.[OHl] The examples described below are intended to be merely exemplary, and those skilled in the art will recognize, or will be able to ascertain using no more than routine experimentation, numerous equivalents of specific compounds, materials, and procedures. All such equivalents are considered to be within the scope of the claimed subject matter and are encompassed by the appended claims.EXAMPLESExample 1: Compound 1 Efficacy in a Preclinical SOD1 Mouse Study: Disease Onset and Age of Paralysis

[0112] Compound 1 was administered at a dosage of 6 mg / kg in a SOD1-G93A transgenic mice study relative to an isotype control. See FIG. 1. The SOD1-G93A transgenic mouse line was used with Compound 1 therapy beginning at 12 weeks of age, coincident with the onset of symptoms. Each treatment group consisted of 24 female mice, receiving a once daily oral dose (6mg / kg) of Compound 1 until death.

[0113] Compound 1 significantly extended the time to onset of disease and increased the age of paralysis relative to isotype control.

[0114] The Compound 1 -treated mice showed first clinical signs of disease at day 35, versus day 24 for the Isotype control (p < 0.01).

[0115] The onset of paralysis for Compound 1 -treated mice was delayed to day 37, versus the onset of paralysis was day 27 for the Isotype control (p <0.01).Example 2: Compound 1 Efficacy in a Preclinical SOD1 Mouse Study: Time to First Death and Improved Survival

[0116] Compound 1 was administered at a dosage of 6 mg / kg in a SOD1-G93A transgenic mice study relative to an Isotype control. See FIG.2.

[0117] Treatment with Compound 1 significantly delayed the time to first death (p<0.01 ) in SOD1 mice versus Isotype control.

[0118] Treatment with Compound 1 also significantly improved survival (p=0.1) in SOD1 mice versus Isotype control.

[0119] Accordingly, Compound 1 demonstrated functional and survival benefit in the SOD 1 mouse model, the most aggressive mouse model of ALS. The SOD1 preclinical model remains the gold standard in experimental ALS in vivo models as it most closely recapitulates key28NAI-5002374383vlaspects of the pathophysiology of the disease, including progressive paralysis, respiratory failure and lethality associated with toxic protein aggregates in neurons and neuroinflammation marked by glial cell activation.Example 3: Compound 1 effects in motor function

[0120] Mice were also tested for motor function using beam walk and rotarod assays. See FIGS. 3A and 3B. A non-significant trend towards improved performance was seen in the rotarod assay as the time to fall was increased by Compound 1 treatment. A similar trend was seen in the beam walk assay where Compound 1 treated mice had a lower number of slips and increased speed scores indicative of better motor function. These assays suggested better strength and coordination in Compound 1 treated mice vs vehicle. The body weight of mice was similar between Compound 1 and vehicle treated groups (data not shown) suggesting no significant gastrointestinal toxicity, a common side effect of MEK inhibitors.Example 4: Preclinical Data in Cancer Models further Supported Use of Compound 1 in treatment of ALS

[0121] Compound 1 has shown to have a better safety profile than trametinib while displaying similar efficacy.

[0122] In a preclinical cancer xenograft study (FIGS. 4A and 4B), Compound 1 was compared to trametinib. Trametinib, sold under the brand name Mekinist®, is a MEK inhibitor used to treat certain types of cancer, which is currently under investigation in the treatment of ALS (https: / / clinicaltrials.gov / study / NCT04326283). As shown in FIGS. 4A and 4B, both Compound 1 and trametinib completely suppressed hepatocellular tumor growth, but in contrast to Compound 1, trametinib caused weight loss consistent with known gastrointestinal toxicity of trametinib. The better tolerability of Compound 1 over trametinib warrants the evaluation of Compound 1 in an ALS proof-of-concept trial.

[0123] Further, cancer studies were used to establish the pERK pharmacodynamic assay to translate findings into the ALS study described here. The cancer studies focused on determining the maximal efficacy doses of the ALS trial. Specifically, samples from lung cancer xenografts were analyzed and showed that pERK reduction correlated with the efficacy of doses, with reductions ranging from 21-75% pERK (FIGS. 5A and 5B).Example 5: Compound 1 Safety and Tolerability Study in humans

[0124] This study focuses on determining whether Compound 1 is safe and well-tolerated in humans and to determine the best dose to use in a larger clinical trial. People with ALS29NAI-5002374383vlwill be enrolled and followed over approximately 28 weeks. Participants will be divided into groups, with each group getting a gradually higher dose of Compound 1 (after checking the safety and tolerability of the previous dose). In addition to assessing safety and tolerability, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) scores and neurofilament light chain (NfL) levels will be evaluated to see if there are any early signs that the treatment is working.

[0125] Specific Aims:• 1 : To test Compound 1 safety in patients with ALS, (i.e., Compound 1 needs to be well-tolerated and present a good safety profile, monitoring of dose- limiting toxicities, monitoring of CSF PK, etc.)• 2: To test Compound 1 effect in ALS biomarkers (i.e., observe changes in plasma neurofilament light chain (NfL), observe evidence of target engagement (reductions in pERK levels).Example 6: Biomarkers Exploration

[0126] Biomarkers of target engagement

[0127] The primary pharmacodynamic marker for MEK1 / 2 inhibition is the reduction of ERK1 / 2 phosphorylation. ERK1 / 2 kinases are the primary target of MEK1 / 2 activity and phosphorylated ERK (pERK) is the primary pharmacodynamic marker of MEK activity used in preclinical and clinical studies of MEK inhibitors.

[0128] Blood samples will be collected for measurement of pERK levels by using standard methods known in the art.

[0129] Peripheral-blood mononuclear cells (PBMCs) Processing and Flow Cytometry-Based Assay for MEK Pathway Activation will be used.

[0130] Biomarkers of treatment response

[0131] Markers of treatment response will be assessed in this study. This will include the revised ALS functional rating scale (ALSFRS-R) and plasma neurofilament light chain (NfL). ALSFRS-R is a patient-reported outcome measure of function scored on a 0-to-48-point scale that is routinely used a primary endpoint in phase 3 ALS clinical trials.

[0132] Furthermore, the change from baseline of plasma neurofilament light chain (NfL) will be assessed. NfL is a neuronal specific cytoskeletal protein which is increased in many neurological conditions and can be reliably measured in serum. It is released from axons into the CSF which crosses the blood brain barrier at lower concentrations. Plasma neurofilament30NAI-5002374383vllight chain concentrations correlate with the rate of ALS disease progression and have been used in ALS clinical trials as a secondary outcome measure of efficacy. (See, Steinacker P, Huss A, Mayer B, et al. Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and SIOOB, in the course of amyotrophic lateral sclerosis: data from the German MND-net. Amyotroph Lateral Scler Frontotemporal Degener. 2017 ; 18 ( 1 -2) : 112-119; Verde F, Steinacker P, Weishaupt JH, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(2):157-164; Poesen K, Van Damme P. Diagnostic and prognostic performance of neurofilaments in ALS. Front Neurol. 2018;9:l 167). Measurements will be performed using standard methods.

[0133] Inflammatory markers will be monitored. Inflammatory markers include, but are not limited to IFN-y, IL- 1 , IL-2, IL-4, IL-6, IL- 10, IL-23, IL-12p70, IL- 17 A, TNF-a. For example, assay set-up and sample analysis for quantitating i) TNF-a, ii) IL1 0, iii) IL-6, and iv) IL-23 in human CSF samples will be performed using standard methods known in the art. Generally, the inflammatory markers will be evaluated from serum, and / or plasma, and / or cell culture supernatant, and / or CSF, and / or urine samples.

[0134] The embodiments provided herein are not to be limited in scope by the specific embodiments provided in the examples which are intended as illustrations of a few aspects of the provided embodiments and any embodiments that are functionally equivalent are encompassed by the present disclosure. Indeed, various modifications of the embodiments provided herein are in addition to those shown and described herein will become apparent to those skilled in the art and are intended to fall within the scope of the appended claims.

[0135] A number of references have been cited, the disclosures of which are incorporated herein by reference in their entirety.31NAI-5002374383vl

Claims

CLAIMSWhat is claimed:

1. A method of treating amyotrophic lateral sclerosis, comprising administering a therapeutically effective amount of (5R,6S)-10,ll-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide or a pharmaceutically acceptable salt or solid form thereof (Compound 1), to a patient having amyotrophic lateral sclerosis, wherein the structure of Compound 1 is:

2. A method of treating amyotrophic lateral sclerosis, comprising administering to a patient having amyotrophic lateral sclerosis a tablet formulation comprising about 1% to about 10% of (5R,6S)-10,ll-difhioro-12-((2-fhioro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-lH-spiro[benzo[b][l,5,4]oxathiazecine-3,l'-cyclopropane] 2,2-dioxide or a pharmaceutically acceptable salt or solid form thereof (Compound 1), about 42% to about 46% microcrystalline cellulose, about 22% to about 26% lactose monohydrate, about 13% to about 17% pregelatinized starch, about 8% to about 12% crospovidone, about 0.3% to about 0.7% colloidal silicon dioxide, and about 0.05% to about 0.7% magnesium stearate, where the percentages are by weight based on total weight of the tablet.

3. The method of claim 1 or 2, wherein the solid form comprises a free base of Compound 1.

4. The method of any one of claims 1 to 3, wherein the solid form is characterized by an XRPD pattern comprising peaks at approximately 8.5, 9.2, 12.0, 15.1, 17.0, 18.3, 20.8, 22.0, 24.1, and 27.4° 20.

5. The method of any one of claims 1 to 4, wherein Compound 1 is administered as a tablet formulation having a weight of 1 mg, 4 mg, or 10 mg.32NAI-5002374383vl6. The method of any one of claims 1 to 4, wherein about 1 mg, about 4 mg, or about 10 mg of Compound 1 is administered to the patient.

7. The method of any one of claims 1 to 6, comprising determining the plasma level of neurofilament light chain (NfL) in the patient.

8. The method of claim 7, wherein Compound 1 reduces the plasma level of NfL in the patient.33NAI-5002374383vl